FDA OKs New Drug to Combat Melanoma

Thursday, 04 Sep 2014 04:50 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
Merck & Co. on Thursday won the first U.S. approval for a new kind of cancer drug with big advantages over chemotherapy and other older cancer treatments.
 
The Food and Drug Administration said it has granted accelerated approval to Merck's Keytruda, for treating melanoma that's spread or can't be surgically removed, in patients previously treated with another cancer drug.

The genetically engineered drug, known chemically as pembrolizumab, is part of a hot, promising new class of antibody-based drugs. They work by taking a brake off the immune system so it can better recognize and attack cancer cells.
 
Special: Prescription Drugs: Are You Taking Too Many?

"Ninety percent of patients have basically no side effects," Dr. Antoni Ribas, a UCLA researcher who was the lead investigator of a crucial study of Keytruda, told The Associated Press in an interview.

By comparison, most patients getting chemotherapy suffer with nausea, vomiting and hair loss.

In addition, Ribas said, Keytruda and other "immune-therapy" drugs appear likely to work against many more types of cancer than older drugs, and in a much higher percentage of patients. In a study of 600 patients, one-third of them benefited from the drug, with 62 percent of those alive after 18 months.

Chemotherapy drugs have an average survival of about nine months, while some newer cancer drugs on average keep patients alive for 11 to 15 months, he noted.

"This is just the start," Ribas said, adding that earlier tries at immune therapy for cancer typically helped only 5 to 10 percent of patients.

Merck's drug is the first in the class of what's called anti-PD-1 drugs approved in the U.S.
Bristol-Myers Squibb Co. and a partner have a drug similar to Keytruda, called Opdivo, that was approved in Japan in July. They are seeking U.S. approval for it.
 
Special: Prescription Drugs: Are You Taking Too Many?


© Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Novo's Long-Acting Diabetes Drug Effective in Trial

Tuesday, 16 Sep 2014 08:19 AM

Novo Nordisk's new long-acting insulin Tresiba has been shown to be effective and safe for long-term use in children and . . .

Exercise Delays Age-Related High Blood Pressure by a Decade

Tuesday, 16 Sep 2014 08:07 AM

Aerobic exercise leading to strong heart fitness can delay a man's onset of age-related high blood pressure by nearly a  . . .

Researchers ID 9 Critical Steps to Heart Attack Survival

Tuesday, 16 Sep 2014 08:00 AM

People who've had a heart attack are at greater risk of death if even one of nine critical steps in their treatment is m . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved